Boston Scientific reported first-quarter sales that exceeded the company’s forecast, saying it gained market share across its businesses as demand for procedures using its medical devices rebounded from a year ago.
The company raised its full-year sales and profit forecasts, based on its first-quarter performance.
“We believe that all business units grew faster than their respective markets, with differentiated portfolios and a strong commercial execution supported by healthy procedural demand,” CEO Mike Mahoney told analysts Wednesday on the company’s conference call.
